Adoptive T‐cell transfer in cancer immunotherapy

Publisher Website
Google Scholar
Abstract
Adoptive T‐cell therapy has definite clinical benefit in relapsed leukaemia after allogeneic transplant and in Epstein–Barr virus‐associated post‐transplant lymphoproliferative disease. However, the majority of tumour targets are weakly immunogenic self‐antigens and success has been limited in part by inadequate persistence and expansion of transferred T cells and by tumour‐evasion strategies. Adoptive immunotherapy presents the opportunity to activate, expand and genetically modify T cells outside the tolerising environment of the host and a number of strategies to optimize the cellular product, including gene modification and modulation of the host environment, in particular by lymphodepletion, have been developed.
Funding Information
  • National Institutes of Health (PO1 CA94237)
  • Haematology Society of Australia and New Zealand